DUBLIN--(BUSINESS WIRE)--The "Uveitis - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Uveitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 3, 8, 6, 1, 25 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Uveitis - Overview
- Uveitis - Therapeutics Development
- Uveitis - Therapeutics Assessment
- Uveitis - Companies Involved in Therapeutics Development
- Uveitis - Drug Profiles
- Uveitis - Dormant Projects
- Uveitis - Discontinued Products
- Uveitis - Product Development Milestones
- Appendix
- Aciont Inc
- Aldeyra Therapeutics Inc
- Alvotech Iceland
- Apitope International NV
- Bristol-Myers Squibb Co
- Clearside BioMedical Inc
- Coherus BioSciences Inc
- Elasmogen Ltd
- Enzo Biochem Inc
- EyeGate Pharmaceuticals Inc
- EyePoint Pharmaceuticals Inc
- Eyevensys SAS
- F. Hoffmann-La Roche Ltd
- Fresenius SE & Co KGaA
- Galapagos NV
- HanAll Biopharma Co Ltd
- Idera Pharmaceuticals Inc
- Johnson & Johnson
- Kv1.3 Therapeutics
- Midatech Pharma Plc
- Mitotech SA
- Nemus Bioscience Inc
- Novartis AG
- OncoNOx ApS
- Ophthotech Corp
- Orchid Pharma Ltd
- Palatin Technologies Inc
- Panoptes Pharma GesmbH
- Re-Pharm Ltd
- Sandoz International GmbH
- Santen Pharmaceutical Co Ltd
- Sun Pharma Advanced Research Company Ltd